AZ examining the effects of travel on employees; Pfizer's India unit posts a quarterly dip on plant lockout;

@FiercePharma: Top-read in FiercePharmaMarketing Weds: Sanofi revamps 'underperforming' U.S. sales team under new diabetes chief. Article | Follow @FiercePharma

@EricPFierce: Boehringer Ingelheim unloads US API plant to Chinese company even as it expands in China. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's FiercePharmaMarketing newsletter. Subscribe to get it weekly. | Follow @CarlyHFierce

> AstraZeneca ($AZN) is researching the effects of travel on its employees' well-being to see whether there's is a link to recruitment and retention. More

> Pfizer's ($PFE) Indian unit reported a quarterly loss thanks to expenses related to a lockout at its manufacturing plant in Mumbai. Report

> Swedish drugmaker Meda posted a higher-than-expected third-quarter core profit and raised its margin outlook for 2014. Report

> Jordan's Hikma Pharmaceuticals raised its full-year revenue growth target to 7%, citing strong demand for its high-margin injectible drugs. More

> CEO of Hungarian drugmaker Richter, Erik Bogsch, said the company expects full-year revenues to fall by 5% to 6% from last year, compared with a previous forecast for a 6% to 7% drop. More

> Slovenia's Krka posted a 9-month group net profit of €127.4 million ($159 million), up 2% from the same period last year. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic in high spirits over positive study results for drug-coated balloon. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Government report says device tax will not deter innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Medtronic in high spirits over positive study results for drug-coated balloon. More | Follow @EmilyWFierce

> Dexcom snags FDA approval for next-gen artificial pancreas tech for blood glucose monitoring system. Report

> Stryker agrees to pay $1.43B to settle recalled hip implant lawsuits. Story

> Dozens of lawsuits filed in growing counterfeit spinal screw implant scandal. Article

Biotech News

@FierceBiotech: Merck partners with Bind on a pair of new cancer drug programs. News | Follow @FierceBiotech

@JohnCFierce: Aeterna Zentaris bottoms out after a stinging FDA rejection--$AEZS down 51%. More | Follow @JohnCFierce

@DamianFierce: So $ABBV's not disclosing a PDUFA date for its HCV combo, but its June priority review disclosure puts in mid Dec. June release | Follow @DamianFierce

@EmilyMFierce: Glaxo hep C vaccine delivers promising early results. FierceVaccines story | Follow @EmilyMFierce

> GlaxoSmithKline's effort to re-launch cancer R&D faces skepticism. Item

> Spark snags a 'breakthrough' tag for its Phase III gene therapy. More

> Tolero wraps up a $22.4M round to support its cancer contender. Article

Pharma Manufacturing News

> Two more guilty pleas in spectacular burglary of Lilly warehouse. News

> Valeant labeling snafu affects Sanofi's Aplenzin, as well as Valeant's vaseretic. Report

> Ranbaxy manufacturing mess costs it exclusive for Valcyte generic. More

> Baxter spends $10M expanding admixing facility in Canada. Story

> German meat company invests $30M in plant for traceable heparin ingredients. Article

Vaccines News

> Inhaled Ebola vaccine may provide higher protection rate. News

> Sanofi, armed with more strong PhIII dengue data, sets sights on 2015 rollout. Report

> Glaxo hep C vaccine delivers promising early results. Story

> Sanofi, Protein Sciences win flu jab nods in older adults. Item

> PATH Malaria Vaccines Initiative nets $156M from Gates Foundation. Article

And Finally... Switzerland is distributing iodide tablets to more than half the country's population for use in the event of a nuclear disaster. More

Suggested Articles

FDA researchers uncover more concerns and fears among front-line workers and minority groups about a COVID-19 vaccine.

As COVID-19 vaccines advance, the FDA held an expert hearing Thursday to talk safety, efficacy, distribution plans and vaccine confidence—plus more. 

Moderna, racing ahead with COVID-19 vaccine R&D, completed enrollment for its late-stage trial—and moved one step closer to approval.